By Heather Hobbs


BRINGING YOU THE LATEST NEWS & EVENTS FROM THE SCIENCE INDUSTRY


Project to Advance Understanding in Particle Physics


A four year European Community project structured to address open questions in the strong interaction studies in theory and experiment – a cornerstone of the Standard Model (SM) of particle physics - has received EU approval under the Horizon 2020 framework and funding of €10 million.


Attracting an active community of about 2500 researchers in Europe, such questions include a full understanding of the three-dimensional structure of the proton; the spectroscopy of hadrons and their exotic states; the properties of the hot and dense quark-gluon plasma; precision studies of the SM. These research topics are experimentally studied mostly by particle collisions at low (GeV range) and high (up to 14 TeV) energies, which require continuous developments in state- of-the-art detectors, data acquisition systems, beams and targets, as well as in the underlying theory.


The STRONG-2020 project, set to build upon and go beyond the previous Hadron Physics HP, HP2 and HP3 projects in the framework programmes of FP6 and FP7, is strongly supported by NuPECC (the Nuclear Physics European Collaboration Committee) and will provide transnational access to six world-class research infrastructures in Europe, which


complement each other in particle beams characteristics (COSY, MAMI, LNF-INFN, ELSA, GSI, CERN) and virtual access to open-source codes and automated/simulation tools. The project consortium includes 44 participant institutions, embracing 14 EU Member States, one International EU Interest Organization (CERN) and one EU candidate country (Montenegro).


Together with host institutions of other 21 countries, participating in the activities without EU benefits, STRONG-2020 involves research in 36 countries. Contributing to fundamental research for physics beyond SM, the project will impact in other scientific sectors, such as astrophysics and theories of strongly coupled complex systems in condensed matter; provide new tools and methodologies that will upgrade European Research Infrastructures, while developed technologies will also impact in medicine (diagnostic tools, cancer treatment) and industry (line-scan cameras, 3D-magnets technology) and may also lead to advances in computing/machine learning.


49529pr@reply-direct.com


CEM India 2019 Now Open for Registration


Over 700 visitors attended the 2017 event


Visitors to CEM India 2019 (New Delhi 24-26 September) can now register online at www.cemindia.com. Focusing on continuous emissions monitoring, the event will provide access to information on new Indian environmental regulations, along with the latest monitoring methods and technologies for reliable regulatory compliance.


MilliporeSigma Advance Biotech Grant Program Winners Announced


MilliporeSigma has announced the winners of its Advance Biotech Grant program in North America during its Biotech Start-up Summit at the Cambridge Innovation Center. The grant is given to small- and mid- size biotechnology companies that need funding and expertise to get their therapies to market.


“With more than 60% of drugs in the pipeline today being developed by biotechs, we are committed to supporting these start-ups in developing groundbreaking therapeutics,” said Udit Batra, CEO, MilliporeSigma. “Our global grant program provides free access to our process development expertise, products and services to help accelerate molecule-to-market efforts.”


The three grant recipients are:


RAFT Pharmaceuticals for its approach to treat chronic pain using a biologic to selectively inhibit neuroinflammation without affecting normal motor or sensory function.


Rubicon Biotechnology for developing a therapeutic protein, Fv-Hsp72, designed to protect and salvage cells damaged from an acute event, such as traumatic brain injury.


TechnoVax Inc for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, haemorrhagic fevers, immunodeficiency and cancers.


Applicants from biotech companies across US and Canada were asked to describe their projects, the medical needs they solve and process development challenges they face to be considered for the grant. In support of the growing biotech ecosystem, grant recipients receive between $40,000 and $100,000 in MilliporeSigma products and process development support.


“Rubicon is honoured to have been selected as a winner in the Advance Biotech Grant,” said Richard Richieri, President of Rubicon Biotechnology. “Under the resources provided by this grant, we intend to develop a robust and scalable downstream process to purify our pre- clinical recombinant protein, Fv-Hsp72, by utilising the various chromatography resins and filters offered by MilliporeSigma. Our objective is to use a bench-scale version of our process from bioreactor to drug substance for our in vitro and in vivo studies that will mimic our subsequent large- scale GMP process.”


MilliporeSigma selected the winning submissions based on the scientific and societal merit of therapy in development and process challenges and expertise gaps. The program is part of the company’s global biotech commitment to help bring therapies to market, leveraging decades of process development expertise products, and support at any production scale. Additionally, MilliporeSigma’s BioReliance®


End-to-End Services can


address key challenges for biotech companies at all stages of molecule development and commercialisation in any geography.


MilliporeSigma began the grant program in 2014. The rotating program runs every six months, in Europe, North America or Asia. To date, MilliporeSigma has awarded more than $1.2 million in products and services to 20 biotech companies in these regions. Earlier this year, our grants supported companies in Europe in tackling glioblastoma brain tumours and cardiovascular disease. Biotech companies in Asia with a molecule in development should apply before 15 August 2019 for the next round of grant funding.


49373pr@reply-direct.com


The Indian Central Pollution Control Board (CPCB) is responsible for the planning and execution of a nationwide programme for the prevention, control or abatement of water and air pollution, and a speaker from CPCB will open the conference by providing an update on the implementation of Continuous Emission Monitoring Systems (CEMS) in India.


With new environmental regulations on both emissions to air and water, a broad spectrum of Indian industries will have to implement reliable monitoring programmes to demonstrate compliance. Consequently, there is an enormous requirement for monitoring equipment and technology, so CEM 2019 will be an ideal opportunity for Indian companies, consultants, regulators and researchers to find the best and most cost-effective solutions to their monitoring needs.


Following the extraordinary success of the 2017 event, organiser Marcus Pattison said: “In addition to air emissions, the 2019 event will also address the monitoring of industrial effluent, so we have had to enlarge the exhibition space, but at the time of writing only a handful of stands remain available.


“With leading international technology manufacturers signing up to attend, CEM 2019 will provide a unique opportunity to see the whole world of environmental monitoring at the same time, under one roof.”


Over 700 visitors attended the 2017 event, 95% of which were looking to purchase monitoring equipment. Feedback from the visitors was unanimously positive; for example, a CPCB visitor said: “It was a wonderful learning experience. I learned a lot about the certified technologies relating to the advanced CEM technologies that have been adopted worldwide.”


The CEM India 2019 Conference will provide visitors with detailed information on emissions monitoring, and the Exhibition will enable them to discuss practical monitoring issues with industry experts. As a consequence CEM India 2019 will be an essential event in the diary of anyone affected by the new Indian environmental regulations.


49451pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60